Arcus Biosciences RCUS
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 46th percentile, 5-year average 1.6x
Near the top of its 5-year range · 95th percentile, 5-year average 3.3x
#4717 of 5330 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 90th percentile, 5-year average 12.6x
#4775 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.01 | – | 3.29 | 95% (pricier than usual) | #4717 of 5330 (1 = cheapest) |
| PE | -4.79 | -5.49 | 1.59 | 46% (cheaper than usual) | – |
| PS | 25.10 | 114.26 | 12.58 | 90% (pricier than usual) | #4775 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on RCUS.
Sign in to join the discussion.